Thursday, November 12, 2026

Israel, Nigeria Central Banks Join Global Shift Toward Rate Cuts as ECB Watches Euro

Israel's central bank governor committed to cautious rate cuts despite political pressure, joining Nigeria, South Korea, and Thailand in a coordinated global easing trend. ECB's Kocher signaled openness to further cuts if euro appreciation dampens inflation, marking a sharp reversal from the 2022-2023 tightening cycle that spanned developed and emerging markets.

ViaNews Editorial Team

February 24, 2026

Source Trace Score4 source documents4 with a live linkVerifiability: Strong
Israel, Nigeria Central Banks Join Global Shift Toward Rate Cuts as ECB Watches Euro
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Central banks across four continents are pivoting toward rate cuts after two years of synchronized tightening. Israel's Amir Yaron pledged cautious monetary easing while resisting pressure from Finance Minister Bezalel Smotrich, who has demanded faster cuts as economic growth slows.

ECB board member Kocher told markets the bank would cut rates again if euro appreciation proves large enough to reduce inflation forecasts. The statement underscores how currency movements—not just domestic price pressures—now drive policy across major economies. ECB President Christine Lagarde faces parliamentary testimony this week on the bank's easing timeline.

Nigeria's central bank is weighing cuts alongside confirmed moves from South Korea's Bank of Korea and Thailand's central bank. The shift spans developed and emerging markets, contrasting sharply with the aggressive tightening that defined 2022-2023 monetary policy worldwide.

GDP data from India, Germany, and Mexico will test whether officials are cutting preemptively or responding to confirmed weakness. Germany's recovery remains fragile despite recent positive signals, complicating the ECB's calculation on how quickly to ease. Bank of England Governor Andrew Bailey also testifies this week to clarify the UK's policy path.

For banks, lower rates compress lending margins but could boost loan volumes if growth stabilizes. Credit markets may see investors chase yield as rates fall, tightening spreads across asset classes.

Columbia economist Michael Woodford noted that cost-of-living comparisons require examining absolute wage and price levels, not inflation rates—a reminder that rate cuts affect real economic conditions differently than nominal price changes suggest.

The coordinated easing indicates central banks now prioritize growth over lingering inflation concerns. Whether cuts prove premature depends on forthcoming data and how quickly looser policy translates into credit expansion and business investment.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score4 source documents4 with a live linkVerifiability: Strong
  1. [1]News articleYahoo Finance· February 21, 2026
    Germany About to Find Out Whether Its Recovery Is Real
  2. [2]News articleYahoo Finance· November 28, 2025
    Scott Bessent says ‘move from a blue state to a red state’ is No. 1 way to beat inflation, leaving critics stunned
  3. [3]News articleNasdaq· January 29, 2026
    Stocks Finish Mixed as Fed Keeps Interest Rates Steady
  4. [4]News articleSeeking Alpha· January 30, 2026
    Catalyst Watch: Amazon earnings, IPO blitz, gold swings, and the jobs report

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com